Legacy Financial Strategies LLC Invests $219,000 in Thermo Fisher Scientific Inc. $TMO

Key Points

• Legacy Financial Strategies LLC has acquired 539 shares of Thermo Fisher Scientific valued at approximately $219,000.
• The company reported Q2 earnings of $5.36 per share, exceeding analyst expectations of $5.22, with a revenue of $10.86 billion.
• Thermo Fisher Scientific's dividend of $0.43 per share will be paid on October 15, representing a 0.4% yield and a payout ratio of 9.95%.

Legacy Financial Strategies LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 539 shares of the medical research company's stock, valued at approximately $219,000.

A number of other hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Thermo Fisher Scientific by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock valued at $16,659,627,000 after purchasing an additional 230,382 shares during the period. Amundi grew its holdings in Thermo Fisher Scientific by 5.9% during the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after acquiring an additional 168,197 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Thermo Fisher Scientific by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after acquiring an additional 115,463 shares during the period. Pictet Asset Management Holding SA grew its holdings in Thermo Fisher Scientific by 7.2% during the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after acquiring an additional 193,378 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after acquiring an additional 329,974 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the transaction, the chief executive officer directly owned 113,762 shares of the company's stock, valued at $56,937,881. The trade was a 0.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TMO. Raymond James Financial reaffirmed an "outperform" rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Barclays upgraded Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $490.00 to $550.00 in a research report on Thursday, September 11th. UBS Group raised their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research report on Friday, July 11th. Finally, Evercore ISI decreased their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Sixteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $588.35.

Thermo Fisher Scientific Trading Down 0.2%

NYSE:TMO traded down $1.08 on Friday, reaching $480.02. The company's stock had a trading volume of 4,241,401 shares, compared to its average volume of 1,433,914. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The firm has a market cap of $181.26 billion, a price-to-earnings ratio of 27.76, a price-to-earnings-growth ratio of 2.56 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $623.77. The stock has a 50 day moving average price of $472.01 and a 200 day moving average price of $449.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.